WuXi AppTec Expands Drug Development Testing Services

Published on: 

The expanded Laboratory Testing Division, located in Cranbury, NJ, will expand the company’s testing services in the United States.

On April 18, 2018, WuXi AppTech announced the opening of its expanded Laboratory Testing Division facility in Cranbury, NJ. The expansion will increase total operation space to more than 115,000 square feet, including laboratories for preclinical and clinical drug development testing. The combined operations of the new Cranbury site and the company’s site in Plainsboro, NJ, will support discovery and development involving drug metabolism and pharmacokinetics (DMPK) and bioanalytical studies.

The new DMPK facility in Cranbury is 54,583 square feet and will feature automation, e-platform, non-GLP BA for biomarkers and large molecules, and pharmacokinetics/pharmacodynamics (PK/PD) capabilities. Other services include early- and late-stage definitive in vitro administration, distribution, metabolism, and elimination (ADME) studies, rodent PK/PD for all states, biotransformation, and radiolabel mass balance and QWBA in rodents.

The expansion was celebrated with a ribbon cutting ceremony attended by the Honorable Glenn Johnson, Mayor of Cranbury; the Honorable Peter Cantu, Mayor of Plainsboro; Dr. Jijun Xing, science and technology consul at the Chinese Consulate in New York; and Debbie Hart, president and CEO of BioNJ.

“The Garden State continues to be an important life science hub. This expansion will allow our team to deliver high quality service with faster turnaround times, better leverage the resources and expertise of the local pharmaceutical and biotechnology community, and develop a stronger connection with our customers,” said Dr. Jason Liu, SVP of WuXi AppTec and chief operating officer of the LTD, in a press release.


“We are delighted for this opportunity to better serve our global customers and to support local economic development in New Jersey,” said Dr. Ge Li, chairman and CEO of WuXi AppTec. “We will continue to enhance WuXi’s capabilities and capacities to enable our global partners to discover and develop drugs more efficiently and cost effectively ultimately benefitting patients worldwide.”

Source: WuXi AppTec